RayKnowChina Research Map
Shortlist

RecruitingLymphomaPhase 2

Registered title, quoted from ClinicalTrials.gov

Venetoclax as Consolidation in CLL Patients Treated With BTK Inhibitor Monotherapy

An open trial on lymphoma, registered on ClinicalTrials.gov. Led by Jiangsu Province Hospital; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorJiangsu Province Hospital江苏省人民医院(南医大一附院)NanjingHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT06958705, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 7

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (7 points)Hide the checklist
  1. 18 years to 80 years; sex: all

    Registered eligibility fields

  2. NYHA functional class ≤ 2.

    Inclusion criterion 18

  3. 2. Active malignancy requiring systemic therapy, other than CLL, with the exception of: adequately treated in situ carcinoma of the cervix uteri; adequately treated basal cell carcinoma or localized squamous cell carcinoma of the skin; previous malignancy confined and surgically resected (or treated with other modalities) with curative intent.

    Exclusion criterion 2

    3. Major surgery, radiotherapy, chemotherapy, biologic therapy, immunotherapy, experimental therapy within 3 weeks prior to the first dose of the study drug.

    Exclusion criterion 3

    11. Received other therapeutic agents for CLL/SLL during BTK inhibitor treatment prior to enrollment.

    Exclusion criterion 11

    13. Received strong CYP3A inhibitors or strong CYP3A inducers within 7 days of starting venetoclax.

    Exclusion criterion 13

    15. Prior treatment with venetoclax or other Bcl-2 inhibitor.

    Exclusion criterion 15

  4. 6. Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 2.

    Inclusion criterion 6

  5. Serum bilirubin ≤ 1.5 × upper limit of normal (ULN) or ≤ 3 × ULN for patients with Gilbert's disease;

    Inclusion criterion 8

    Serum creatinine clearance of ≥ 50 ml/min (calculated or measured);

    Inclusion criterion 9

    ALT and AST ≤ 3.0 × ULN, unless clearly due to disease involvement.

    Inclusion criterion 10

    Platelet count of greater than 50,000/µl, with no platelet transfusion in prior 2 weeks;

    Inclusion criterion 12

    ANC ≥ 1000/µl in the absence of growth factor support unless due to compromised bone marrow production from CLL, indicated by ≥ 80% CLL in marrow;

    Inclusion criterion 13

    Hemoglobin ≥ 8g/dL.

    Inclusion criterion 14

  6. 7. Known HIV positive.

    Exclusion criterion 7

    8. Active hepatitis B infection (defined as the presence of detectable HBV DNA or HBe antigen). Patients who are HBsAg positive or HBcAb positive are eligible, provided HBV DNA is negative. These patients must have monthly monitoring of HBV DNA for the duration of the study.

    Exclusion criterion 8

    9. Active hepatitis C, defined by the detection of hepatitis C RNA in plasma by PCR.

    Exclusion criterion 9

  7. 6. Females who are pregnant or lactating.

    Exclusion criterion 6

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; scans and measurable lesions.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06958705, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • 1. Age: 18-80 years-old.
  • 2. Patients must have a diagnosis of CLL/SLL.
  • 3. Detectable MRD by flow cytometry (10\^-4 sensitivity) in the peripheral blood.
  • 4. Patients who are on BTK inhibitor monotherapy for more than 6 months. This study includes patients who are taking one of the following BTK inhibitors: ibrutinib, zanubrutinib, orelabrutinib, and acalabrutinib.
  • 5. Patients need to have a response of at least PR (CR/PR) to BTK inhibitor monotherapy.
  • 6. Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 2.
  • 7. Patients must have adequate renal and hepatic function:
  • Serum bilirubin ≤ 1.5 × upper limit of normal (ULN) or ≤ 3 × ULN for patients with Gilbert's disease;
  • Serum creatinine clearance of ≥ 50 ml/min (calculated or measured);
  • ALT and AST ≤ 3.0 × ULN, unless clearly due to disease involvement.
  • 8. Adequate bone marrow function:
  • Platelet count of greater than 50,000/µl, with no platelet transfusion in prior 2 weeks;
  • ANC ≥ 1000/µl in the absence of growth factor support unless due to compromised bone marrow production from CLL, indicated by ≥ 80% CLL in marrow;
  • Hemoglobin ≥ 8g/dL.
  • 9. Adequate cardiac function, as assessed by:
  • Absence of uncontrolled cardiac arrhythmia;
  • Echocardiogram demonstrating LVEF ≥ 35%;
  • NYHA functional class ≤ 2.
  • 10. Ability to provide informed consent and adhere to the required follow-up.

Exclusion Criteria:

  • 1. Richter transformation.
  • 2. Active malignancy requiring systemic therapy, other than CLL, with the exception of: adequately treated in situ carcinoma of the cervix uteri; adequately treated basal cell carcinoma or localized squamous cell carcinoma of the skin; previous malignancy confined and surgically resected (or treated with other modalities) with curative intent.
  • 3. Major surgery, radiotherapy, chemotherapy, biologic therapy, immunotherapy, experimental therapy within 3 weeks prior to the first dose of the study drug.
  • 4. Grade 3 or 4 hemorrhage within the past 3 weeks.
  • 5. Uncontrolled active infections (viral, bacterial, and fungal).
  • 6. Females who are pregnant or lactating.
  • 7. Known HIV positive.
  • 8. Active hepatitis B infection (defined as the presence of detectable HBV DNA or HBe antigen). Patients who are HBsAg positive or HBcAb positive are eligible, provided HBV DNA is negative. These patients must have monthly monitoring of HBV DNA for the duration of the study.
  • 9. Active hepatitis C, defined by the detection of hepatitis C RNA in plasma by PCR.
  • 10. Active, uncontrolled autoimmune phenomenon (autoimmune hemolytic anemia or immune thrombocytopenia) requiring steroid therapy > 20 mg prednisone daily or equivalent, within 7 days of starting venetoclax.
  • 11. Received other therapeutic agents for CLL/SLL during BTK inhibitor treatment prior to enrollment.
  • 12. Concurrent use of warfarin or equivalent vitamin K inhibitor or other oral anticoagulant treatment.
  • 13. Received strong CYP3A inhibitors or strong CYP3A inducers within 7 days of starting venetoclax.
  • 14. Consuming grapefruit, grapefruit products, Seville oranges, or star fruit within 7 days of starting venetoclax.
  • 15. Prior treatment with venetoclax or other Bcl-2 inhibitor.
  • 16. Malabsorption syndrome or other condition that precludes enteral route of administration.

Quoted from ClinicalTrials.gov, NCT06958705, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT06958705, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT06958705